Numbers (percentages) of patient consultations over a one year period for which an integrated care pathway was completed (by condition and clinical genetics centre)
| Centre 1 | Centre 2 | Centre 3 | Centre 4 | Total | |
| Tuberous sclerosis | 21/23 (91%) | 5/9 (55%) | 0/3 | 6/9 (67%) | 32/44 (73%) |
| Marfan syndrome | 29/39 (74%) | 5/10 (50%) | 20/43 (46%) | 21/41 (51%) | 75/133 (56%) |
| Myotonic dystrophy | 12/15 (80%) | 12/15 (80%) | 2/4 (50%) | 5/41 (12%) | 31/75 (41%) |
| Neurofibromatosis type 1 | 34/43 (79%) | 31/65 (48%) | 17/27 (63%) | 10/20 (50%) | 92/155 (59%) |
| Total | 96/120 (80%) | 53/99 (53%) | 39/77 (51%) | 42/111 (38%) | 230/407 (57%) |